THE PROBLEM OF COMPATIBILITY AND SAFETY OF EXCIPENTS AND SUBSTANCES IN PARENTERAL (INJECTABLE) DOSAGE FORMS

Download full text PDF
DOI: https://doi.org/None
Issue: 
8
Year: 
2015

Professor S.Ya. Skachilova (1), PhD; O.I. Teryoshkina (2*), PhD; Professor I.P. Rudakova (2), PhD; Professor E.V. Shilova (1), PhD; Professor I.A. Samylina (2), PhD 1 -All-Russian Research Center for Safety of Biologically Active Substances; 23, Kirov St., Staraya Kupavna, Moscow Region 143450; 2 -Research Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University; 8, Trubetskaya St., Build. 2, Moscow 119991

The important aspects of the safety of use of parenteral dosage forms are the compatibility of components and the safety of excipients. Chemically active pharmaceutical substances and excipients in the manufacture of their formulations can be subject to redox destruction. This may give rise to compounds having different chemical and biological properties and stability, which affect the therapeutic efficacy of drugs. The paper considers the problem of compatibility and safety of excipients and substances in injectable dosage forms, as well as the examples of incompatibility of the components of formulations and the requirements for the safety of excipients to design current parenteral drugs. It gives contraindications to and possible side effects of the excipients that are extensively used in the injectable dosage forms.
Keywords: 
parenteral dosage forms
compatibility
excipients
substances
References: 
  1. Gosudarstvennaya farmakopeya RF, XII izd., chast` 1. M.: Nauchnyy centr e`kspertizy sredstv medicinskogo primeneniya, 2008: 707.
  2. Gosudarstvennaya farmakopeya SSSR, XI izd. Vyp.2. M.: Medicina, 1990; 397.
  3. The European Pharmacopoeia, 9-th ed. Strasburg, 2015.
  4. The United States Pharmacopoeia. National Formulary (USP 37). The United States Pharmacopoeial Convention, 2014.
  5. Perechen` zhiznenno neobhodimyh i vazhneyshih lekarstvennyh preparatov. Utv. Rasporyazheniem Pravitel`stva RF № 2199-r ot 07.12.2011 i rasporyazheniyami № 1378-r ot 30.07.2012 i № 2782-r ot 30.12.2014.
  6. Skachilova S.Ya., Rudakova I.P., Il`ina I.G., Shilova E.V., Samylina I.A., Tencova A.I. Biofarmacevticheskie aspekty farmakopeynyh substanciy. Farmaciya, 2012; 8: 29–32.
  7. Remko M. Molecular structure and stability of perindopril erbumine and perindopril L-arginine complexes. Eur. J. Med. Chem., 2009 Jan; 44 (l): 101–108.
  8. Tencova A.I., Tereshkina O.I., Rudakova I.P., Samylina I.A., Gus`kova T.A. Sovremennye biofarmacevticheskie aspekty vspomogatel`nyh veshhestv. Farmaciya, 2012; 7: 3–6.
  9. Patel H., Shah V., Upadhyay U. New pharmaceutical excipients in solid dosage forms. A review. Jut. J. of Pharm., 2011; 2: 8.
  10. Patent RF №234345, opubl. 20.03.2009, byul. 5.
  11. Handbook of Pharmaceutical Excipients (Edited by: Raymond C. Rowe, Paul J. Sheskey, Marian E. Quinn) UK, USA. Pharmaceutical Press and American Pharmacists Association. Electronic version. 2009.
  12. Tekeshwar K., Shailendra K.G., Mukesh K.P. et al. Natural excipients: A review. J. of Pharm and Life Sci., 2012; 2: 97–108.
  13. Bagirova V.L., Demina N.B., Devyatkina I.A., Tencova A.I., Denisov V.A.. Sovremennye aspekty ispol`zovaniya vspomogatel`nyh veshhestv v tehnologii lekarstvennyh preparatov. Farmateka, 1998; 6: 34–36.
  14. Bharate S.S., Bharateb S.B., Bajaj A.N. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J.Exc. and Food chem., 2010; 1 (3).
  15. Pifferi J. Restani P. The safety of pharmaceutical excipients. 1.1. Farmaco, 2003; 58: 541–550.
  16. Titova A.B. Vspomogatel`nye veshhestva, ispol`zuemye v proizvodstve lekarstvennyh preparatov. Standartizaciya i metody kontrolya. Dis. dokt. farm. nauk. M., 2006; 312.
  17. Mashkovskiy M.D. Lekarstvennye sredstva, 16 izd. M.: Novaya volna, 2010; 505.
  18. Inactive Ingredient Search for Approved Drug Products. http//www.accessdata.fda:gov.scripts.eder(iig)gettingWEB.Cfm. 24.04.2014
  19. Rukovodstvo po bezopasnosti vspomogatel`nyh veshhestv. CPMC, USA, 463/00. 2003.